Susan Dallabrida named to PharmaVOICE 100
PHT has announced Susan Dallabrida, Ph.D., vice president of clinical science and consulting, is among this year’s PharmaVOICE 100 most inspiring professionals in the life sciences industries. Dallabrida is the 6th PHT executive to earn a place on the list. PHT is a provider of technologies used to collect patient-driven eData for clinical research.
Established 10 years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the industry. Dallabrida was chosen for her scientific expertise in offering the pharma, biotech and life sciences industries a combination of vision and practicality in using eClinical technologies that drive efficiencies within pragmatic research.
Philip Lee, PHT president and CEO, who was a 2011 PharmaVOICE 100 honoree, said, “Dallabrida has a well-earned reputation for leadership in developing technologies to provide evidence, data analysis and creative solutions that result in huge improvements in study design that is focused on the patient.”
Dallabrida has over 21 years of experience as a senior scientist, consultant and leader in clinical research and development, trial design and strategy and product development. She has significant regulatory experience for biologics and small molecules. Dallabrida has led cross-functional drug discovery and product development teams and collaborations in therapeutic areas including oncology, cardiovascular disease, hemophilia, dermatology, obesity and vascular disorders. She has a broad background in scientific presentations and writing with 21 publications, 14 grants, 3 patents, 18 awards, 43 conference presentations and 29 abstracts.